Under construction – not a live service
Sign in
Not yet taking people in SpainNo phase

Studying risk factors to help detect lung cancer earlier

Builds prediction models to spot lung cancer early, using risk tools, devices and cell analysis.

Plain-language title generated from the registry record
Registry title: Understanding Lung Cancer Related Risk Factors and Their Impact

Key facts

Where
Barakaldo and Seville, SpainSee the 3 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

Source: NCT06473870, who can take part

Where in Spain

  • Hospital Universitario CrucesBarakaldo, SpainNo longer taking part
  • Aljarafe-Sevilla Norte Health DistrictSeville, SpainNo longer taking part
  • Hospital Universitario Virgen MacarenaSeville, SpainNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Biobizkaia Health Research Institute
Trial code
NCT06473870
Record updated
25 June 2024
Original description
LUCIA aims to develop prediction models for the early diagnosis of lung cancer based on the identification of risk factors and deeper cellular knowledge, by recording real-world data; with risk assessment tools, non-invasive devices and omics analysis. These models will enable new clinical pathways and diagnostic workflow to be implemented to ensure early diagnosis and confirmation, including classification of lung cancer subtype.Read full original descriptionShow less

Understanding Lung Cancer Related Risk Factors and Their Impact

LUCIA aims to develop prediction models for the early diagnosis of lung cancer based on the identification of risk factors and deeper cellular knowledge, by recording real-world data; with risk assessment tools, non-invasive devices and omics analysis. These models will enable new clinical pathways and diagnostic workflow to be implemented to ensure early diagnosis and confirmation, including classification of lung cancer subtype.

Inclusion: Subjects aged between 40 and 80 years; Both genders, of which at least 37% must be women to ensure representativeness; Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures; Written informed consent obtained prior to performing any protocol-related procedures; High risk of developing Lung Cancer volunteers will be selected by Lung Cancer risk factors modelling; Patients diagnosed with indeterminate pulmonary nodules or Lung Cancer from the screening phases.

Exclusion: Current or prior history of lung cancer; History of neoplasia in the previous 5 years except non-melanoma skin cancer; Moderate-severe comorbidities that prevent completion of a diagnostic study in the event of findings suggestive of lung neoplasia (by means of the investigator's clinical judgment) or surgical intervention (< 6 months) if not previously confirmed by cytohistology; Vulnerable subjects: severe psychiatric comorbidity, adults under guardianship or deprived of liberty; Subjects under 40 years of age; Unable to be followed-up for at least 2-years or complete the study; Subjects that do not sign the informed consent; Pregnant women.

ClinicalTrials.gov NCT06473870